Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
05 2020
Historique:
received: 22 08 2019
revised: 08 12 2019
accepted: 07 02 2020
pubmed: 29 2 2020
medline: 8 7 2021
entrez: 29 2 2020
Statut: ppublish

Résumé

Lipid traits have been inconsistently linked to risk of non-Hodgkin lymphoma (NHL). We examined the association of genetically predicted lipid traits with risk of diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) using Mendelian randomization (MR) analysis. Genome-wide association study data from the InterLymph Consortium were available for 2,661 DLBCLs, 2,179 CLLs, 2,142 FLs, 824 MZLs, and 6,221 controls. SNPs associated ( HDL was positively associated with DLBCL (OR = 1.14; 95% CI, 1.00-1.30) and MZL (OR = 1.09; 95% CI, 1.01-1.18), while TG was inversely associated with MZL risk (OR = 0.90; 95% CI, 0.83-0.99), all at nominal significance ( We did not find evidence of a clear or strong association of these lipid traits with the most common NHL subtypes. While these IVs have been previously linked to other cancers, our findings do not support any causal associations with these NHL subtypes. Our results suggest that prior reported inverse associations of lipid traits are not likely to be causal and could represent reverse causality or confounding.

Sections du résumé

BACKGROUND
Lipid traits have been inconsistently linked to risk of non-Hodgkin lymphoma (NHL). We examined the association of genetically predicted lipid traits with risk of diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) using Mendelian randomization (MR) analysis.
METHODS
Genome-wide association study data from the InterLymph Consortium were available for 2,661 DLBCLs, 2,179 CLLs, 2,142 FLs, 824 MZLs, and 6,221 controls. SNPs associated (
RESULTS
HDL was positively associated with DLBCL (OR = 1.14; 95% CI, 1.00-1.30) and MZL (OR = 1.09; 95% CI, 1.01-1.18), while TG was inversely associated with MZL risk (OR = 0.90; 95% CI, 0.83-0.99), all at nominal significance (
CONCLUSIONS
We did not find evidence of a clear or strong association of these lipid traits with the most common NHL subtypes. While these IVs have been previously linked to other cancers, our findings do not support any causal associations with these NHL subtypes.
IMPACT
Our results suggest that prior reported inverse associations of lipid traits are not likely to be causal and could represent reverse causality or confounding.

Identifiants

pubmed: 32108027
pii: 1055-9965.EPI-19-0803
doi: 10.1158/1055-9965.EPI-19-0803
pmc: PMC7196490
mid: NIHMS1562300
doi:

Substances chimiques

Lipoproteins, HDL 0
Lipoproteins, LDL 0
Triglycerides 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1074-1078

Subventions

Organisme : Blood Cancer UK
ID : 15037
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : N01 PC067009
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182934
Pays : United States
Organisme : NCI NIH HHS
ID : N01 PC067008
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES000260
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP000807
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA134674
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000026C
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA092049
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000140C
Pays : United States
Organisme : NCI NIH HHS
ID : N01 PC067010
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA098122
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG007033
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000035C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA134958
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA129539
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA154643
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA062006
Pays : United States
Organisme : NCI NIH HHS
ID : N01 PC065064
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA092153
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000035I
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000034C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA049449
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA200703
Pays : United States
Organisme : NCI NIH HHS
ID : N01CO12400
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA149445
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA118444
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Cancer Res. 2007 Jun 1;67(11):5569-74
pubmed: 17522388
Nat Genet. 2017 Dec;49(12):1758-1766
pubmed: 29083408
Nat Genet. 2014 Nov;46(11):1233-8
pubmed: 25261932
Epidemiology. 2014 May;25(3):427-35
pubmed: 24681576
Cancer Causes Control. 2018 Jan;29(1):143-156
pubmed: 29192350
Am J Hum Genet. 2014 Oct 2;95(4):462-71
pubmed: 25279986
Nat Commun. 2016 Mar 09;7:10933
pubmed: 26956414
Cancer Causes Control. 2012 Oct;23(10):1693-703
pubmed: 22907421
Nat Commun. 2015 Jan 08;6:5751
pubmed: 25569183

Auteurs

Geffen Kleinstern (G)

Mayo Clinic, Rochester, Minnesota.

Nicola J Camp (NJ)

Department of Internal Medicine, Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City, Utah.

Sonja I Berndt (SI)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Brenda M Birmann (BM)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Alexandra Nieters (A)

Institute for Immunodeficiency, Medical Center - University of Freiburg, Freiburg, Germany.

Paige M Bracci (PM)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

James D McKay (JD)

International Agency for Research on Cancer, Lyon, France.

Hervé Ghesquières (H)

Department of Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite, France.

Qing Lan (Q)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Henrik Hjalgrim (H)

Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark.

Yolanda Benavente (Y)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.

Alain Monnereau (A)

Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, Epidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France.

Sophia S Wang (SS)

City of Hope Beckman Research Institute, Duarte, California.

Yawei Zhang (Y)

Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.

Mark P Purdue (MP)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Anne Zeleniuch-Jacquotte (A)

Department of Population Health and Perlmutter Cancer Center, NYU School of Medicine, New York, New York.

Graham G Giles (GG)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Precision Medicine, Monash University, Melbourne, Victoria, Australia.

Roel Vermeulen (R)

University Medical Center Utrecht, Utrecht, the Netherlands.

Pierluigi Cocco (P)

Department of Medical Sciences and Public Health, Occupational Health Section, University of Cagliari, Monserrato, Italy.

Demetrius Albanes (D)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Lauren R Teras (LR)

American Cancer Society, Atlanta, Georgia.

Angela R Brooks-Wilson (AR)

BC Cancer, Vancouver, and Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada.

Claire M Vajdic (CM)

Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.

Eleanor Kane (E)

Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, Heslington, York, United Kingdom.

Neil E Caporaso (NE)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Karin E Smedby (KE)

Karolinska Institutet, Division of Clinical Epidemiology, Department of Medicine Solna, Stockholm, Sweden.

Gilles Salles (G)

Department of Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite, France.

Joseph Vijai (J)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Stephen J Chanock (SJ)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Christine F Skibola (CF)

Emory University, Atlanta, Georgia.

Nathaniel Rothman (N)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

Susan L Slager (SL)

Mayo Clinic, Rochester, Minnesota.

James R Cerhan (JR)

Mayo Clinic, Rochester, Minnesota. cerhan.james@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH